FDA Issues Guidance For Psychedelic Drug Trials

Axios reports:

Federal regulators are laying out guidance for psychedelic drug trials for the first time, in a move that could encourage the mainstreaming of substances like magic mushrooms and LSD as behavioral health treatments.

Psychedelics are turning into a multi-billion industry and gaining widespread acceptance after decades of concerns about recreational use of the products — and the high risk for misuse. But research to date has largely been backed by private sponsors.

The Food and Drug Administration on Friday released first-ever draft guidance outlining considerations — including trial conduct, data collection and subject safety — for researchers looking into psychedelic treatments for a variety of conditions, including PTSD, depression and anxiety.

Read the full article.

FDA creates path for psychedelic drug trials https://t.co/39JsAnwju9

— Patricia Farrell, Ph.D. (@drpatfarrell) June 26, 2023